Mutations in genes connected with the TCF7L2 transcription factor are associated with a poor prognosis in Non-Small Cell Lung Cancer

Personalized, or precision, medicine has transformed medical oncology for lung cancer patients. Personalized medicine involves the molecular characterization of a patient ’s tumor by targeted next-generation sequencing (NGS) to direct treatment options that will provide the best outcome for the patient[1]. NGS sequencing for advanced lung cancer is now standard in clinics, and various commercial vendors provide clinical multiplexed NGS services. Clinical trials hav e shown the survival benefits of molecular profiling for those patients with the common actionable mutations, i.e.

Source: Lung Cancer - January 12, 2020 Category: Cancer & Oncology Authors: Shawn J. Rice, Xin Liu, Victoria Hyland, Zhenqiu Liu, Chandra P. Belani Source Type: research